Latest news with #tirzepatide
Daily Telegraph
18 hours ago
- Health
- Daily Telegraph
TGA approves Mounjaro as first medicine registered to treat obstructive sleep apnoea in adults with obesity
Don't miss out on the headlines from Lifestyle. Followed categories will be added to My News. A new drug is expected to be approved by Australia's Therapeutic Goods Association (TGA) as the first ever prescribed medicinal treatment for Obstructive Sleep Apnoea (OSA). The medicine, called Mounjaro (tirzepatide) is designed specifically to treat adults with OSA - a disease which affects around 780,000 Australians. The drug is designed specifically to help treat people who are diagnosed with OSA as a result of obesity given the strong link that exists between both conditions. Andrew Beveridge with the machine that helps him breath at night during sleep. Picture: Tricia Watkinson Respiratory and sleep specialist Professor Brendon Yee said the drug was a 'treatment option' for patients with moderate-to-severe OSA. 'You wouldn't use this medication in sleep apnoea patients who are not obese - which is maybe about 20% of patients,' Professor Yee said. 'There isn't one kind of treatment for the disease…it's important to assess patients based on what the best treatment is for them. Sometimes it may be a combination of things, for instance a combination of weight loss plus a trial of CPAP (continuous positive airway pressure) machines,' he said. 'Mounjaro is private script only, it's TGA approved. It's based on a sleep study and patients have to have obesity… it has the advantage that people can lose weight… but you have to sustain that weight loss.' Damon Sedgwick works in IT and loves performing in amateur theatre - something he found himself doing less and less after he was diagnosed with OSA. 'My partner noticed I was snoring in bed and I would stop breathing at times. I went and had a sleep study and was diagnosed with OSA,' Mr Wedgwick said. 'I tried to use a CPAP…I was using it and I did have a lot of success, but I was still overweight and I still had a dependence on the machine. It was a bit of a burden,' he said. Mounjaro fat-loss drug. Picture: Supplied 'A professor put me in touch with the Woolcock Institute…they said there's a new drug they're trialling and I said yes… the outcome of that after I finished was that I lost about 50 kilos.' Mr Sedgwick said he was able to reclaim the parts of his life which had been put on hold. 'It made a massive difference to my life. I don't snore at night anymore. I used to wake up 60 times on any given night, and now I barely do it once. It's good to be able to move - even walking to the shops is easy now,' he said. 'It's not a miracle shot. It's not a magic bullet, you have to work hard. I still have to watch what I eat and drink, I still have to exercise. It can't be used in isolation, you have to put the hard yards in.' Do you have a story for The Daily Telegraph? Message 0481 056 618 or email tips@
Medscape
a day ago
- Business
- Medscape
GLP-1 Less Frequent Dosing May Maintain Weight Loss
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) administered at off-label reduced dosing maintained weight-loss benefits, with patients retaining the effects even with 2-4 weeks between doses. METHODOLOGY: GLP-1 RAs are transforming obesity treatment, but high costs and shortages limit patient access. Clinicians have suggested a less frequent dosing to maintain weight loss, but evidence supporting its effectiveness is lacking. Researchers used a combination of real-world case reports and mathematical modeling to examine the efficacy of a less frequent dosing of GLP-1 RAs for weight maintenance. They analyzed the data of two patients who used GLP-1 RAs at less frequent dosing schedules than recommended; patient 1 with obesity and prediabetes self-administered 7.5 mg tirzepatide every 10-14 days, whereas patient 2 with uncontrolled type 2 diabetes managed intermittent dosing of 15 mg tirzepatide due to supply shortages. A mathematical pharmacokinetic-pharmacodynamic model was used to simulate long-term changes in body weight of virtual patients administered semaglutide and tirzepatide at various dosing intervals. Simulations modeled semaglutide (2.4 mg) or tirzepatide (5 mg, 10 mg, or 15 mg) as a once-weekly dosing for 120 weeks, after which the 7-day dosing interval was increased to 10, 14, or 28 days or retained. TAKEAWAY: Patient 1 achieved an additional 13.7% body weight loss over 7 months and maintained it thereafter. Patient 2 lost 30% of her body weight and safely stopped insulin; even with intermittent dosing of tirzepatide, she retained a 22.8% body weight loss from baseline. Mathematical modeling predicted that switching from one dose per week to one dose every 2 weeks maintained 72% and 78% of the body weight loss achieved with 2.4 mg semaglutide and 15 mg tirzepatide, respectively. Even monthly dosing may have preserved half of the body weight loss achieved with weekly dosing, demonstrating that the reduction in efficacy was not proportional to the reduction in dosing frequency. IN PRACTICE: 'Future studies are needed to identify patient factors that predict a more favorable response to less frequent dosing of incretin mimetics and to examine the long-term clinical outcomes achieved through this approach compared with other off-ramping options (eg, switching to alternative AOMs [anti-obesity medications]),' the authors wrote. SOURCE: This study was led by Calvin C. Wu, Tono Health, Brooklyn, New York. It was published online in Obesity . LIMITATIONS: No limitations were provided for this study. DISCLOSURES: Two authors reported receiving funding from the National Science Foundation. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. Credit Lead image: KKfotostock/Dreamstime Medscape Medical News © 2025 WebMD, LLC Cite this: Edited by Javed Choudhury. GLP-1 Less Frequent Dosing May Maintain Weight Loss - Medscape - June 03, 2025.
Daily Mail
3 days ago
- Health
- Daily Mail
Woman who lost six stone on Mounjaro reveals the horrible side effects no one talks about
A woman in her twenties has lost six stone in just nine months thanks to weight loss jabs - but it wasn't without some very unpleasant side effects. Bethany Diana, from the UK, went from a size 18 to a size eight after starting on Mounjaro (tirzepatide) in July 2024. But the 27-year-old, who says she is 'such a better version' of herself for having shed the weight, hasn't shied away from revealing the downsides of using the fat jab. Mounjaro is typically prescribed to patients with type two diabetes. The NHS has warned that it should be used only by those who have been prescribed it. Bethany, who has racked up more than 75,000 likes on TikTok, took to the platform to share the 10 side effects she's experienced since beginning her weight loss journey. In a clip that has been viewed 109,000 times, the content creator revealed that she has suffered with diarrhoea as a result of Mounjaro. Just as troublingly, Bethany, who goes by @bethanydianax on TikTok, has experienced bad breath. In addition, the young brunette struggled with hair loss during her weight loss journey, though she did not give an insight into how severe this symptom was. Another, particularly unpleasant, side effect was what Bethany called 'Sulphur burps'. Sulfur burps, the name given to burps which have a rotten egg smell, occur when there is hydrogen sulfide gas in the gut. She has also suffered with constipation, nausea, heartburn, wind and reflux, she said in the clip entitled 'Some of my side effects since being on Mounjaro'. Finally, Bethany told how the jabs suppressed her appetite - the medication aids weight loss by making the patient feel fuller for much longer than usual. In a subsequent TikTok clip, Bethany told viewers: 'Mounjaro stole my booty'. A number of people on medications like Mounjaro have complained that their behinds have become saggy as a result of the relatively rapid weight loss. However, she appears to have no regrets about using the jabs. In the caption to the clip, she wrote: 'But on the plus side I did lose six stone in nine months and I am such a better version of myself'. Viewers were quick to share their own experiences of side effects in the comments section beneath Bethany's clip, with a number echoing her symptoms. One person wrote: 'It's the sulphur burps and the feeling of nausea which I cannot stand especially when I'm hardly eating anything to cause it. Still on the plus side, weight is coming off well'. Another person said: 'Yes, I have bad breath. I did not know it was from the injection'. While a third wrote: 'I'm on week two and the only side effect I've had is a bit of constipation. Feel like I have been lucky'. Perhaps unsurprisingly, Bethany's clip listing the side effects of Mounjaro prompted one person to wonder if it was all worth it. The TikTok user asked: 'Why would you do it then?!' In her response, Bethany pointed out that the side effects were 'temporary' while the weight loss was 'for life'. While Bethany has reported a positive experience on Mounjaro, more than 80 Brits have died after using weight-loss and diabetes jabs such as Ozempic and Mounjaro. The Medicines and Healthcare Products Regulatory Agency reported at least 22 fatalities linked to the medication up to the end of January. A further 60 deaths were recorded for products aimed to help with Type 2 diabetes. Nearly 400 people also required hospital treatment since the rollout of the products over the past few years. The NHS has warned patients to 'never take an anti-obesity medicine if it has not been prescribed to you'. Susan McGowan, a 58 year-old nurse from Lanarkshire, died from multiple organ failure, septic shock and pancreatitis after taking two low-dose injections of tirzepatide. She took the jabs for a two-week period before her death on September 4 last year. It is thought to be the first time the medicine has been listed as a contributing factor on a death certificate.
Fox News
27-05-2025
- Entertainment
- Fox News
Comedian Jim Gaffigan admits he lost 50 pounds using Mounjaro
Jim Gaffigan made a bold admission about his weight-loss journey. The 58-year-old confessed that his transformation was less about willpower and more about convenience, as he credited Mounjaro (tirzepatide) for shedding 50 pounds. "I did appetite suppressants, so it's not like I can even take any pride in it," the comedian shared on "Today." "I was brave enough to stick a needle in my stomach," he joked. The injectable prescription medicine is primarily used to treat type 2 diabetes. "The Skinny" comedian used to weigh 270 pounds, according to People. Despite not taking pride in his weight-loss transformation, he pointed out the benefits Mounjaro has had on his body. "It's great because my knees don't hurt standing up," he explained. "I'm less exhausted… It's always good, you know, like the health benefits, like, 'I'll live longer,'" "But I love it just because I feel better," he said. "It is great. It's beneficial." Gaffigan previously had reservations about the medication. "I had very low expectations because I did know someone that had tried it, and they were like, 'Oh no, I was just nauseous for a week,'" he told People at the time. "I thought my true joy of eating would overpower anything," Gaffigan admitted. "That's some of [the] why I wanted to talk about it, because I almost thought it was kind of odd that people were resistant to talking about it. I don't think there's anything wrong with it." Gaffigan isn't the only celebrity who credited Mounjaro for their slimmed-down figure. Rosie O'Donnell, 63, recently took to social media to share a photo of herself performing stand-up and acknowledging her much smaller frame. "I can't believe this is me now," she captioned the photo, which included the hashtags "#mounjaro,"#weightloss" and "#bodydismorphia." Comedian Amy Schumer additionally praised the effects of Mounjaro in a video clip shared on Instagram in March. In a previous attempt to lose weight, the comedian said she experienced debilitating side effects while using Ozempic for weight-loss purposes. "I wanted to share and keep it 100 with you, that years ago… I tried Wegovy, and I was like puking," said Schumer. "I couldn't handle it…" she referred to her previous weight-loss prescription. However, things appeared to take a turn when she switched to Mounjaro. "My hair is fuller, my skin is better, I have more energy, I want to get down more if you know what I mean – I'm talking about sex." Schumer added, "So that's been great, Mounjaro's been great… I'm having a really good experience with it and I wanted to keep it real with you about that."
Associated Press
27-05-2025
- Health
- Associated Press
Zuellig Pharma Launches Lilly's Innovative Obesity and Diabetes Medicine in Thailand
Mounjaro® (tirzepatide) will be available in the market from the end of May 2025 BANGKOK, THAILAND - Media OutReach Newswire - 27 May 2025 - Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro® (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be launched in Thailand at the end of May 2025. Zuellig Pharma holds the marketing authorization for Mounjaro® (tirzepatide) in Thailand, having been granted the distribution and promotion rights for the medicine by Eli Lilly and Company this year. Mounjaro® (tirzepatide) is a once-weekly prescription-only medicine indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise; as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in addition to other medicinal products for the treatment of diabetes; and as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). The availability of Mounjaro® (tirzepatide) is a significant advancement in the treatment of both obesity and type 2 diabetes, offering a single medication that can address both conditions through an easy-to-use prefilled pen. Mounjaro® KwikPen® (tirzepatide injection) is available in 2.5 mg, 5 mg, 7.5 mg and 10 mg, and gives healthcare providers the ability to personalize treatment plans better to meet individual patient needs. Obesity is a critical public health concern in Thailand that affects 48% of the total population.2 The Ministry of Public Health classifies obesity as a Non-Communicable Disease (NCD) due to its strong link to rising rates for chronic illnesses, particularly type 2 diabetes. In 2024, the Department of Disease Control reported that 1 in 10 Thai individuals – a total of 6.5 million people – suffer from type 2 diabetes, impacting their physical, mental, and social well-being.2 People with diabetes face significant challenges in managing their blood sugar and preventing complications such as cardiovascular disease, chronic kidney disease, diabetic retinopathy, and diabetic foot ulcers, which can lead to severe infections and potential amputation.3 'Obesity and diabetes have gained prominence as significant health challenges in Thailand, and we are excited to accelerate the availability of Mounjaro® (tirzepatide) to patients in the region. With our deep understanding of the local regulatory landscape, as well as our proven track record of delivering innovative healthcare solutions in unmet disease areas, we are well placed to enhance the availability of the medicine in the market. This represents a significant step forward in our commitment to making healthcare more accessible, particularly in the chronic metabolic disease market,' said Rehan Saghir, Executive Vice President of Zuellig Pharma's Commercialization division. References: Hashtag: #ZuelligPharma #EliLillyandCompany #Diabetes #Obesity #Healthcare #Pharmaceuticals The issuer is solely responsible for the content of this announcement. About Zuellig Pharma Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multibillion-dollar business covering 17 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world. For more information, visit:
